FDA Approves Dectomax-CA1 for Treatment and Prevention of NWS Infestations in Cattle
U.S. Food and Drug Administration (FDA) shared on LinkedIn:
”Today, we conditionally approved the first drug for the prevention and treatment of New World screwworm (NWS) larval infestations as well as the prevention of NWS reinfestation for 21 days.
This conditional approval is limited for use in cattle and demonstrates the Agency’s dedication to rapidly facilitating access to important animal health products.”
New World Screwworm infestations, first re-emerging in Central America in 2024, have spread north through Mexico in 2025, with cases now detected as far as Nuevo Leon near the U.S. border.
The outbreak threatens regional cattle industries, prompting livestock movement restrictions, sterile fly release programs, and strict U.S.–Mexico border surveillance.
On September 30, 2025, the U.S. Food and Drug Administration conditionally approved Dectomax-CA1 for the prevention and treatment of New World screwworm (NWS) larval infestations in cattle.
The drug is available as an injectable solution and provides protection against reinfestation for up to 21 days.
Doramectin, the active ingredient, is a macrocyclic lactone that targets the parasite’s nervous system by selectively binding to glutamate-gated chloride channels.
This binding leads to hyperpolarization of nerve and muscle membranes, resulting in paralysis and death of the parasite.
Its longer half-life, due to greater lipophilicity and enhanced tissue distribution, underlies its prolonged activity, which represents a key advantage over other similar agents.
Read more on the topic here.
More on latest FDA approvals in the field of Hematology featured in Hemostasis Today.
-
Oct 6, 2025, 04:10EAHAD PT Committee Chair Ruth Elise Is Contributing to The Discussion On Joint Health and Mobility At EHC 2025
-
Oct 6, 2025, 03:44Caitlin Raymond: When We Talk About Plasma Exchange, Most Discussions Stop At What We’re Removing, But That’s Only Half The Story
-
Oct 6, 2025, 03:20Gianluigi Pasta On Cutting-Edge Cartilage Engineering for Bleeding Disorders Community at EHC 2025
-
Oct 5, 2025, 12:02Joseph Raffaele: Everyone Asks Me About Testosterone. Few Ask About DHEA
-
Oct 5, 2025, 11:58Dr Shamee Shastry and Team Establish New Insights on Critical Antibody Titers
-
Oct 6, 2025, 03:48New Insights On Pre-Existing AAV5 Abs in Haemophilia B Gene Therapy
-
Oct 6, 2025, 03:40Emmanuel J Favaloro and Leonardo Pasalic's Commentary On Acquired von Willebrand Syndrome in Children
-
Oct 5, 2025, 16:40Dr. Kalpana Gupta Shekhawat Insights About Leucovorin and how it Works on the Brain
-
Oct 5, 2025, 12:43Nita Radhakrishnan and Colleagues on Tertiary Prophylaxis with Extended Half-life Factor in LMIC Settings
-
Oct 5, 2025, 12:15Laura Avila and Colleagues on Childhood DVT: Upper Extremity (UE) Post-thrombotic Syndrome (PTS)
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 2, 2025, 04:572025 Innovators Award: Ile de France Région Recognizes 3 Researchers Who Have Committed Themselves to The Innovation
-
Oct 1, 2025, 15:59Anirban Sen Gupta: Thrilled to share a great collaboration story in Nature Portfolio
-
Oct 6, 2025, 03:57Mattia Galli - Nominated Among The Top 200 of 200,000 Leading Researchers Worldwide for The 2025 USERN Prize!
-
Oct 6, 2025, 03:46Marilena Vrana: I Want to Thank Grifols Deutschland for The Opportunity to Visit Their Premises and Biotest AG Manufacturing Facility in Dreieich
-
Oct 6, 2025, 03:43Maha Othman: Real-World Learning Is Essential in Preparing Our Future Nurses!
-
Oct 6, 2025, 03:10Moath Albliwi to Present 4 Major Posters at 67th ASH Annual Meeting 2025
-
Oct 5, 2025, 12:29Miguel Crato: I Feel I Must Always Be Strong, But That Wears Me Down